Acrivon Therapeutics (ACRV) Expected to Announce Quarterly Earnings on Tuesday

Acrivon Therapeutics (NASDAQ:ACRV) is expected to be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its earnings results on Thursday, March 27th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.09. On average, analysts expect Acrivon Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Acrivon Therapeutics Stock Down 1.7%

ACRV stock opened at $1.16 on Monday. The business has a 50 day moving average price of $2.79 and a 200 day moving average price of $5.18. The stock has a market cap of $36.37 million, a price-to-earnings ratio of -0.43 and a beta of 1.88. Acrivon Therapeutics has a fifty-two week low of $1.14 and a fifty-two week high of $10.16.

Insider Buying and Selling at Acrivon Therapeutics

In other news, major shareholder Perceptive Advisors Llc sold 215,283 shares of the company’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $1.56, for a total transaction of $335,841.48. Following the completion of the sale, the insider now owns 4,090,906 shares in the company, valued at $6,381,813.36. This represents a 5.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 1,707,833 shares of company stock worth $3,009,858. 11.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ACRV shares. Piper Sandler started coverage on Acrivon Therapeutics in a research note on Monday, May 5th. They set an “overweight” rating and a $6.00 target price for the company. HC Wainwright reduced their price objective on Acrivon Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Wednesday, March 26th. KeyCorp assumed coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Acrivon Therapeutics in a research note on Wednesday, March 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $19.17.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.